Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Hua Medicine ( (HK:2552) ) is now available.
Hua Medicine announced a significant turnaround in its financial performance for the first half of 2025, reporting an expected profit of RMB1,184.1 million compared to a loss in the same period in 2024. This improvement is attributed to the termination of an agreement with Bayer, leading to a release of contract liabilities, and successful commercialization efforts for HuaTangNing, resulting in a 111.8% increase in sales and improved gross profit margins.
More about Hua Medicine
Hua Medicine is a pharmaceutical company focused on the development and commercialization of innovative therapies for diabetes. The company has assumed full responsibility for the commercialization of HuaTangNing in mainland China, enhancing its market presence in the diabetes treatment sector.
YTD Price Performance: 162.33%
Average Trading Volume: 8,192,394
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.72B
Learn more about 2552 stock on TipRanks’ Stock Analysis page.